ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results